First Patient Completed Two-Year DMX-200 Extension Study
A patient reached the two-year milestone in the open-label extension trial for the treatment of kidney disease.
Updated on Oct. 5, 2026 in Diabetes
Live Poll
Should patients have guaranteed access to experimental drugs after clinical trials conclude?
The first patient has successfully completed two years of treatment in the Dimerix open-label extension study for focal segmental glomerulosclerosis. This extension follows participation in the broader ACTION3 clinical trial.
Why it matters
The study provides essential long-term safety and efficacy data for DMX-200, which is being investigated as a potential treatment for rare kidney conditions. Continued access to the medication is offered to participants through a post-trial scheme.
Over 93% of eligible patients from the 333-person ACTION3 study transitioned into the extension program. Participants receive 120 milligrams of DMX-200 twice daily across 219 global clinical sites.
The players
Dimerix
Dimerix is a clinical-stage biopharmaceutical company that focuses on the development of new treatments for patients with inflammatory diseases.
The details
Patients in the study receive a dosage of 120 milligrams of DMX-200 twice daily after stabilizing their existing angiotensin II receptor blocker intake. The study is conducted across 21 countries and allows participants to continue access to the medication after the primary trial concludes.
Timeline
March 2026: Final adult patient began treatment in the ACTION3 trial.
October 2026: First participant completed two years in the open-label study.
Within 12 months after March 2026: Final adult patient expected to complete full dosing.
The Big Picture
This extension study follows the protocol established by the ACTION3 clinical trial. It extends the longitudinal safety assessments initiated by that primary research program.
The study offers participants continued access to the experimental drug DMX-200 after their initial trial participation ends. These findings help determine if the twice-daily 120-milligram treatment remains safe and effective for long-term use in patients with kidney conditions.
The takeaway
Long-term extension studies are critical for confirming the safety profiles of experimental medications after initial trials are complete. These extensions ensure that patients who contributed to early research maintain a path to ongoing therapy.
What happens next
The remaining adult patients from the ACTION3 trial are projected to complete their dosing schedule within 12 months of March 2026.
Further reading
Learn more about the latest research in the Diabetes section.
Source note: This article includes information reported by Small Caps.
Live Poll
Should patients have guaranteed access to experimental drugs after clinical trials conclude?
